MCID: NSS002
MIFTS: 53

Neisseria Meningitidis Infection

Categories: Infectious diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Neisseria Meningitidis Infection

MalaCards integrated aliases for Neisseria Meningitidis Infection:

Name: Neisseria Meningitidis Infection 54
Meningococcal Disease 54 3
Meningococcal Infections 74
Meningococcal Diseases 56

Classifications:



External Ids:

ICD10 34 A39.9
UMLS 74 C0025303

Summaries for Neisseria Meningitidis Infection

CDC : 3 Meningococcal disease can refer to any illness caused by the type of bacteria called Neisseria meningitidis, also known as meningococcus [muh-ning-goh-KOK-us]. These illnesses are often severe and can be deadly. They include infections of the lining of the brain and spinal cord (meningitis) and bloodstream infections (bacteremia or septicemia).

MalaCards based summary : Neisseria Meningitidis Infection, also known as meningococcal disease, is related to meningococcal meningitis and meningococcemia, and has symptoms including fever and pruritus. An important gene associated with Neisseria Meningitidis Infection is CFP (Complement Factor Properdin), and among its related pathways/superpathways are Innate Immune System and Proteoglycans in cancer. The drugs Ciprofloxacin and Histidine have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and testes, and related phenotypes are hematopoietic system and immune system

Related Diseases for Neisseria Meningitidis Infection

Diseases related to Neisseria Meningitidis Infection via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 105)
# Related Disease Score Top Affiliating Genes
1 meningococcal meningitis 32.4 CFP MBL2
2 meningococcemia 32.3 CFP IL1RN MBL2
3 mannose-binding lectin deficiency 30.6 CFP MBL2
4 complement deficiency 30.6 C3 CFP MBL2
5 complement component 3 deficiency 30.1 C3 CFP
6 haemophilus influenzae 30.1 OMP TLR2
7 glomerulonephritis 29.6 C3 CD46 CFP
8 meningitis 29.3 CFP FCGR2A LACTB MBL2 OMP TLR2
9 pneumonia 28.5 DHPS LACTB MBL2 TLR2 TLR4
10 complement component 8 deficiency 11.7
11 meningococcal infection 11.5
12 properdin deficiency 11.4
13 c3 glomerulopathy 10.3 C3 CFP
14 scabies 10.3 CFP MBL2
15 influenza 10.3
16 deafness, autosomal recessive 24 10.3 EZR MSN
17 peripheral retinal degeneration 10.3 MBL2 ROM1
18 complement factor i deficiency 10.3 C3 CFP
19 coccidioidomycosis 10.2 MBL2 TLR4
20 pouchitis 10.2 IL1RN TLR4
21 3mc syndrome 10.2 CFP MBL2
22 cryopyrin-associated periodic syndrome 10.2 IL1R1 IL1RN
23 trench fever 10.2 TLR2 TLR4
24 schnitzler syndrome 10.2 IL1R1 IL1RN
25 fungal keratitis 10.1 TLR2 TLR4
26 acute cervicitis 10.1 TLR2 TLR4
27 neurofibromatosis, type ii 10.1 EZR MSN TLR2
28 streptococcal meningitis 10.1 CFP IL1R1 MBL2
29 bacteremia 2 10.1 LACTB MBL2
30 complement component 6 deficiency 10.1
31 cardiac tamponade 10.1
32 waterhouse-friderichsen syndrome 10.1
33 suppurative otitis media 10.1 TLR2 TLR4
34 penicilliosis 10.0 TLR2 TLR4
35 tularemia 10.0 MBL2 TLR2
36 aggressive periodontitis 10.0 FCGR2A IL1RN TLR4
37 vulvar vestibulitis syndrome 10.0 IL1R1 IL1RN MBL2
38 myositis fibrosa 10.0 TLR2 TLR4
39 prosthetic joint infection 10.0 MBL2 TLR2 TLR4
40 invasive aspergillosis 10.0 MBL2 TLR2 TLR4
41 aspergillosis 10.0 MBL2 TLR2 TLR4
42 bacterial vaginosis 10.0 MBL2 TLR2 TLR4
43 membranoproliferative glomerulonephritis 10.0 C3 CD46 CFP
44 afibrinogenemia 10.0 C3 CD46 CFP
45 hemolytic uremic syndrome, atypical 1 10.0 C3 CD46 CFP
46 properdin deficiency, x-linked 10.0
47 arthritis 10.0
48 purpura 10.0
49 mycobacterium tuberculosis 1 10.0 MBL2 TLR2 TLR4
50 chorioamnionitis 10.0 IL1R1 IL1RN TLR4

Graphical network of the top 20 diseases related to Neisseria Meningitidis Infection:



Diseases related to Neisseria Meningitidis Infection

Symptoms & Phenotypes for Neisseria Meningitidis Infection

UMLS symptoms related to Neisseria Meningitidis Infection:


fever, pruritus

MGI Mouse Phenotypes related to Neisseria Meningitidis Infection:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.02 C3 DHPS EZR FCGR2A IL1R1 IL1RN
2 immune system MP:0005387 10.02 C3 CFP DHPS EZR FCGR2A IL1R1
3 cardiovascular system MP:0005385 10.01 C3 CD46 CFP IL1R1 IL1RN ROM1
4 mortality/aging MP:0010768 9.96 C3 CFP DHPS EZR FCGR2A IL1R1
5 normal MP:0002873 9.76 C3 CFP DHPS IL1R1 MSN OMP
6 renal/urinary system MP:0005367 9.43 C3 DHPS IL1R1 MBL2 TLR2 TLR4
7 skeleton MP:0005390 9.17 C3 CFP FCGR2A IL1R1 IL1RN TLR2

Drugs & Therapeutics for Neisseria Meningitidis Infection

Drugs for Neisseria Meningitidis Infection (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 50)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ciprofloxacin Approved, Investigational Phase 4,Not Applicable 85721-33-1 2764
2
Histidine Approved, Nutraceutical Phase 4 71-00-1 6274
3
Lactitol Investigational Phase 4,Phase 3,Phase 2,Not Applicable 585-88-6, 585-86-4 493591
4 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
5 Complement Factor H Phase 4
6 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Immunoglobulins Phase 4,Phase 3,Phase 2,Not Applicable
8 Antibodies Phase 4,Phase 3,Phase 2,Not Applicable
9 Heptavalent Pneumococcal Conjugate Vaccine Phase 4,Phase 3,Phase 2
10 Cathartics Phase 4,Phase 3,Phase 2,Not Applicable
11 Laxatives Phase 4,Phase 3,Phase 2,Not Applicable
12 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Cytochrome P-450 Enzyme Inhibitors Phase 4
14 Anti-Infective Agents Phase 4,Phase 3
15 Cytochrome P-450 CYP1A2 Inhibitors Phase 4
16 Anti-Bacterial Agents Phase 4,Phase 3,Not Applicable
17 Topoisomerase Inhibitors Phase 4
18
Hydroxocobalamin Approved Phase 3,Phase 2 13422-51-0 15589840 11953898
19
Acetaminophen Approved Phase 3 103-90-2 1983
20
Pentetic acid Approved Phase 3,Phase 2 67-43-6
21
Iron Approved, Experimental Phase 3,Phase 2 7439-89-6, 15438-31-0 27284 23925
22
Edetic Acid Approved, Vet_approved Phase 3,Phase 2 60-00-4, 62-33-9 6049
23
Tetracycline Approved, Vet_approved Phase 3 60-54-8 5353990
24
Aluminum hydroxide Approved, Investigational Phase 2, Phase 3,Phase 1 21645-51-2
25
Cyanocobalamin Approved, Nutraceutical Phase 3,Phase 2 68-19-9 44176380
26
Cobalamin Experimental Phase 3,Phase 2 13408-78-1 6857388
27 Vitamin B12 Phase 3,Phase 2
28 Vitamin B 12 Phase 3,Phase 2
29 Complement System Proteins Phase 3
30 Pharmaceutical Solutions Phase 3,Phase 2,Phase 1
31 Peripheral Nervous System Agents Phase 3
32 Analgesics Phase 3
33 Analgesics, Non-Narcotic Phase 3
34 Antipyretics Phase 3,Phase 2
35 Anticoagulants Phase 3
36 Protective Agents Phase 3,Phase 2
37 Fibrinolytic Agents Phase 3
38 Antidotes Phase 3,Phase 2
39 Iron Chelating Agents Phase 3,Phase 2
40 PENTA Phase 3,Phase 2
41 Chelating Agents Phase 3,Phase 2
42 Antacids Phase 2, Phase 3,Phase 1
43 Anti-Ulcer Agents Phase 2, Phase 3,Phase 1
44 Adjuvants, Immunologic Phase 2, Phase 3,Phase 1
45
Aluminum sulfate Approved Phase 2 10043-01-3
46 Antibodies, Monoclonal Phase 2
47 Hops Approved Phase 1
48 Natriuretic Agents Not Applicable
49 Natriuretic Peptide, Brain Not Applicable
50 Antibiotics, Antitubercular Not Applicable

Interventional clinical trials:

(show top 50) (show all 264)
# Name Status NCT ID Phase Drugs
1 Investigating the Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba) Unknown status NCT02569632 Phase 4
2 Kinetic of Immune Memory Response After Re-Vaccination With Meningococcal Vaccine Unknown status NCT00262015 Phase 4
3 US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease Completed NCT00282295 Phase 4
4 Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines Completed NCT01270503 Phase 4
5 Understanding the Immune Response to Two Different Meningitis Vaccines Completed NCT01593514 Phase 4
6 Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose Completed NCT01823536 Phase 4
7 Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects From 2 Months to 55 Years of Age in the Republic of South Korea Completed NCT01766206 Phase 4
8 Can we Reduce the Number of Vaccine Injections for Children? Completed NCT01129518 Phase 4
9 Evaluation of Antibody Persistence Following 4 MenACWY Vaccinations Completed NCT02446691 Phase 4
10 Study of Sanofi Pasteur and Lanzhou Institute's Meningococcal (Group A and C) Polysaccharide Vaccine in Children Completed NCT01430611 Phase 4
11 Study on the Impact of Vaccination With a Conjugate Vaccine on Meningococcal Carriage Completed NCT01119482 Phase 4
12 Study Evaluating the Safety and Ability to Produce Immune Response of Prevenar and Meningitec Given at the Same Time Completed NCT00581035 Phase 4
13 Hepatitis B Vaccination in Infants Completed NCT01896596 Phase 4
14 Safety of Purified Meningococcal Vaccine With Serogroups ACWY, in 3,000 Filipino Subjects Aged > 2 Years Completed NCT00290329 Phase 4
15 Immunogenicity of the Booster Dose of Two MenC Vaccines Completed NCT00392808 Phase 4
16 Fractional Dose Tetravalent A, C, Y, W135 Meningococcal Polysaccharide Vaccine Completed NCT00271479 Phase 4
17 Safety, Tolerability and Immunogenicity of Meningococcal C Conjugate Vaccine to Children 32 to 40 Months of Age Completed NCT00310635 Phase 4
18 Safety and Immunogenicity of Intradermal Versus Subcutaneous Doses of Menomune® Completed NCT00850603 Phase 4
19 Persistence of Antibody Response to N. Meningitidis Group C in Children Completed NCT00316654 Phase 4
20 Persistence of Antibodies and Kinetics of B Cell Response in Healthy Children After Vaccination With MCC Vaccine Completed NCT00310713 Phase 4
21 Kinetics of B Cell Response in Infants Menjugate Vaccination Completed NCT00310700 Phase 4
22 Persistence of Immune Response After Vaccination With MCC Completed NCT00310687 Phase 4
23 Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately 4 Years Earlier Completed NCT02633787 Phase 4
24 Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjects Completed NCT02591290 Phase 4
25 Study to Evaluate the Immune Response of United Kingdom (UK) Infants Receiving DTaP/Hib/IPV, Meningococcal C Conjugate and Pneumococcal Conjugate Vaccines, Antibody Persistence and Responses to Booster Doses in the Second Year of Life Completed NCT00625677 Phase 4
26 Response of United Kingdom (UK) Infants to a Reduced Primary Schedule With Meningococcal C and Pneumococcal Conjugate Vaccines Completed NCT00197808 Phase 4
27 Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age Completed NCT01659996 Phase 4
28 Assess the Non-inferiority of GSK Biologicals' Mencevax™ ACWY (Manufactured by a New Process) vs Mencevax™ ACWY (the Already Existing Vaccine in the Market) When Given as a Single Dose to Subjects Aged 2-30 Yrs Completed NCT00227422 Phase 4
29 Ciprofloxacin for the Prevention of Meningococcal Meningitis Completed NCT02724046 Phase 4 Ciprofloxacin
30 A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents Completed NCT01424644 Phase 4
31 South Australian Meningococcal B Vaccine Herd Immunity Study Recruiting NCT03089086 Phase 4
32 Adolescent MenACWY Booster Study Recruiting NCT03694405 Phase 4
33 A Sourcing Study to Collect Human Blood Samples From Healthy Adults Recruiting NCT03493919 Phase 4
34 Evaluation of Safety and Immunogenicity of Meningococcal B and Meningococcal ACWY Vaccine in at Risk Population Recruiting NCT03682939 Phase 4
35 Babies Born Early Antibody Response to Men B Vaccination: BEAR Men B Active, not recruiting NCT03125616 Phase 4
36 Pharmacists as Immunizers to Improve Coverage and Provider/Recipient Satisfaction Active, not recruiting NCT02868970 Phase 4
37 Postmarketing Surveillance Study for Use of Menactra® in the Republic of Korea Active, not recruiting NCT02864927 Phase 4
38 Ciprofloxacin for the Prevention of Meningococcal Meningitis 2018 Not yet recruiting NCT03431675 Phase 4 Ciprofloxacin
39 Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects. Completed NCT02141516 Phase 3
40 A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-Risk Adults Aged 18 to 65 Years Inclusive. Completed NCT01911221 Phase 3
41 Comparison of GlaxoSmithKline (GSK)134612 in Subjects With Increased Risk for Meningococcal Disease Versus Healthy Subjects Completed NCT01641042 Phase 3
42 Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1 Completed NCT01717638 Phase 3
43 Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age. Completed NCT01682876 Phase 3
44 One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age Completed NCT01139021 Phase 3
45 A Phase 3b Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered in Healthy At-risk Adults Completed NCT01478347 Phase 3
46 Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster or as a Two-dose Catch-up to Healthy Toddlers Completed NCT00847145 Phase 3
47 Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents According to Different Vaccination Schedules Completed NCT00661713 Phase 2, Phase 3
48 A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 Years Completed NCT01339923 Phase 3
49 Assessment of Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course in Study V72P10 Completed NCT01148524 Phase 2, Phase 3
50 Safety and Immunogenicity Study for Use of Menactra® Versus Adacel® in Subjects 11 to 55 Years of Age in South Korea Completed NCT01642589 Phase 3

Search NIH Clinical Center for Neisseria Meningitidis Infection

Genetic Tests for Neisseria Meningitidis Infection

Anatomical Context for Neisseria Meningitidis Infection

MalaCards organs/tissues related to Neisseria Meningitidis Infection:

42
Brain, Spinal Cord, Testes, B Cells, Skin, Endothelial, Neutrophil

Publications for Neisseria Meningitidis Infection

Articles related to Neisseria Meningitidis Infection:

(show top 50) (show all 1761)
# Title Authors Year
1
Modeling Neisseria meningitidis Infection in Mice: Methods and Logistical Considerations for Nasal Colonization and Invasive Disease. ( 30877676 )
2019
2
Mbaeyi SA, Joseph SJ, Blain A, Wang X, Hariri S, MacNeil JR. Meningococcal Disease Among College-Aged Young Adults: 2014-2016. Pediatrics. 2019;143(1):e20182130. ( 31040193 )
2019
3
Epidemiology of Meningococcal Disease Outbreaks in the United States, 2009-2013. ( 29982382 )
2019
4
An outbreak of severe invasive meningococcal disease due to a capsular switched Neisseria meningitidis hypervirulent strain B:cc11. ( 30036673 )
2019
5
Invasive meningococcal disease epidemiology and characterization of Neisseria meningitidis serogroups, sequence types, and clones; implication for use of meningococcal vaccines. ( 30156954 )
2019
6
Meningococcal disease in adolescents and young adults: a review of the rationale for prevention through vaccination. ( 30273506 )
2019
7
Invasive meningococcal disease as a cause of sudden and unexpected death in a teenager: The public health importance of confirming the diagnosis. ( 30476492 )
2019
8
The Global Meningococcal Initiative meeting on prevention of meningococcal disease worldwide: Epidemiology, surveillance, hypervirulent strains, antibiotic resistance and high-risk populations. ( 30526162 )
2019
9
Cost calculator for mass vaccination response to a US college campus outbreak of serogroup B meningococcal disease. ( 30526279 )
2019
10
Meningococcal Disease Among College-Aged Young Adults: 2014-2016. ( 30598460 )
2019
11
Carriage rates and risk factors during an outbreak of invasive meningococcal disease due to Neisseria meningitidis serogroup C ST-11 (cc11) in Tuscany, Italy: a cross-sectional study. ( 30621624 )
2019
12
Epidemiological burden of meningococcal disease in Brazil: A systematic literature review and database analysis. ( 30641200 )
2019
13
The cost-of-illness for invasive meningococcal disease caused by serogroup B Neisseria meningitidis (MenB) in Germany. ( 30661834 )
2019
14
Parental Knowledge about Meningococcal Disease and Vaccination Uptake among 0⁻5 years Old Polish Children. ( 30669259 )
2019
15
A systematic review of the diagnostic accuracy of Loop-mediated-isothermal AMPlification (LAMP) in the diagnosis of invasive meningococcal disease in children. ( 30732581 )
2019
16
Healthcare Resource Utilization and Cost of Invasive Meningococcal Disease in Ontario, Canada. ( 30763284 )
2019
17
University-Based Outbreaks of Meningococcal Disease Caused by Serogroup B, United States, 2013-2018. ( 30789140 )
2019
18
Culture and Real-time Polymerase Chain reaction sensitivity in the diagnosis of invasive meningococcal disease: Does culture miss less severe cases? ( 30865671 )
2019
19
Epidemiology of two decades of invasive meningococcal disease in the Republic of Ireland: an analysis of national surveillance data on laboratory-confirmed cases from 1996 to 2016. ( 30869045 )
2019
20
Management of meningococcal outbreaks: are we using the same language? Comparison of the public health policies between high-income countries with low incidence of meningococcal disease. ( 30875482 )
2019
21
Invasive Meningococcal Disease Unraveling a Novel Mutation in the C5 Gene in a Portuguese Family. ( 30882736 )
2019
22
Naval Health Research Center Surveillance for Meningococcal Disease. ( 30901422 )
2019
23
Targeting Type IV pili as an antivirulence strategy against invasive meningococcal disease. ( 30911127 )
2019
24
Lower risk of invasive meningococcal disease during pregnancy: national prospective surveillance in England, 2011-2014. ( 30932328 )
2019
25
The epidemiology and management of clusters of invasive meningococcal disease in England, 2010-15. ( 30942387 )
2019
26
Invasive Meningococcal Disease: What We Should Know, Before It Comes Back. ( 30949522 )
2019
27
Case fatality rates of invasive meningococcal disease by serogroup and age: A systematic review and meta-analysis. ( 30987851 )
2019
28
Standing on the shoulders of giants: two centuries of struggle against meningococcal disease. ( 31053493 )
2019
29
Identification of regulatory variants associated with genetic susceptibility to meningococcal disease. ( 31061469 )
2019
30
US College Students Are at Increased Risk for Serogroup B Meningococcal Disease. ( 31077326 )
2019
31
Epidemiologic burden of meningococcal disease in Latin America: A systematic literature review. ( 31085314 )
2019
32
Potential benefits of using a multicomponent vaccine for prevention of serogroup B meningococcal disease. ( 31102824 )
2019
33
Invasive meningococcal disease due to a non-capsulated Neisseria meningitidis strain in a patient with IgG4-related disease. ( 29606119 )
2018
34
Invasive meningococcal disease without meningitis: a forgotten diagnosis. ( 29695936 )
2018
35
Anticoagulants impact on innate immune responses and bacterial survival in whole blood models of Neisseria meningitidis infection. ( 29977064 )
2018
36
Differential influences of complement on neutrophil responses to Neisseria meningitidis infection. ( 30476070 )
2018
37
An epidemic of meningococcal disease in children in North Norway in the 1970s and 1980s was dominated by a hypervirulent group B strain. ( 29080366 )
2018
38
Potential role of IgM-enriched immunoglobulin as adjuvant treatment for invasive meningococcal disease. ( 29124316 )
2018
39
Current Epidemiology and Trends in Meningococcal Disease-United States, 1996-2015. ( 29126310 )
2018
40
Meningococcal Disease: Vaccines-Who's at Risk and the Future. ( 29200035 )
2018
41
Meningococcal Disease: Vaccines-Who's at Risk and the Future. ( 29200041 )
2018
42
Vaccine prevention of meningococcal disease in Africa: Major advances, remaining challenges. ( 29211624 )
2018
43
Invasive meningococcal disease due to ciprofloxacin-resistant Neisseria meningitidis sequence type 4821: The first case in Japan. ( 29233459 )
2018
44
The ongoing challenge of meningococcal disease. ( 29297936 )
2018
45
Meningococcal disease and control in China: Findings and updates from the Global Meningococcal Initiative (GMI). ( 29406154 )
2018
46
A retrospective assessment of the completeness and timeliness of meningococcal disease notifications in the Republic of Ireland over a 16-year period, 1999-2015. ( 29408188 )
2018
47
Whole genome typing of the recently emerged Canadian serogroup W Neisseria meningitidis sequence type 11 clonal complex isolates associated with invasive meningococcal disease. ( 29414677 )
2018
48
Neonatal meningococcal disease. ( 29450930 )
2018
49
Meningococcal disease and vaccination: Knowledge and acceptability among adolescents in Italy. ( 29452028 )
2018
50
Delayed Generalized Necrotic Purpuric Rash in a C6-deficient 12-year-old Girl Treated for Group W Meningococcal Disease. ( 29474263 )
2018

Variations for Neisseria Meningitidis Infection

Expression for Neisseria Meningitidis Infection

Search GEO for disease gene expression data for Neisseria Meningitidis Infection.

Pathways for Neisseria Meningitidis Infection

Pathways related to Neisseria Meningitidis Infection according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.82 C3 CD46 CFP FCGR2A IL1R1 IL1RN
2 12.06 EZR MSN TLR2 TLR4
3
Show member pathways
12.02 IL1R1 IL1RN TLR2
4
Show member pathways
11.98 IL1R1 TLR2 TLR4
5
Show member pathways
11.98 EZR IL1R1 MSN TLR2 TLR4
6
Show member pathways
11.94 C3 FCGR2A TLR2 TLR4
7
Show member pathways
11.9 C3 CD46 MBL2
8 11.88 C3 CD46 MBL2
9 11.88 C3 FCGR2A TLR2 TLR4
10
Show member pathways
11.84 IL1R1 TLR2 TLR4
11
Show member pathways
11.81 FCGR2A TLR2 TLR4
12
Show member pathways
11.79 IL1R1 TLR2 TLR4
13 11.77 FCGR2A IL1R1 TLR4
14
Show member pathways
11.68 C3 CD46 CFP MBL2
15 11.65 IL1R1 TLR2 TLR4
16
Show member pathways
11.48 C3 CD46 CFP MBL2
17 11.44 C3 FCGR2A MBL2
18 11.32 C3 TLR2 TLR4
19 11.2 C3 FCGR2A MBL2 TLR2 TLR4
20 11.19 C3 FCGR2A TLR2 TLR4
21 10.98 IL1R1 TLR2

GO Terms for Neisseria Meningitidis Infection

Cellular components related to Neisseria Meningitidis Infection according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 vesicle GO:0031982 9.5 EZR IL1RN MSN
2 microvillus membrane GO:0031528 9.26 EZR MSN
3 uropod GO:0001931 9.16 EZR MSN
4 cell surface GO:0009986 9.1 CD46 IL1R1 MBL2 MSN TLR2 TLR4
5 invadopodium GO:0071437 8.96 EZR MSN

Biological processes related to Neisseria Meningitidis Infection according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 neutrophil degranulation GO:0043312 9.96 C3 CFP FCGR2A TLR2
2 immune system process GO:0002376 9.95 C3 CD46 MBL2 TLR2 TLR4
3 positive regulation of gene expression GO:0010628 9.83 CD46 EZR MSN TLR2 TLR4
4 complement activation, classical pathway GO:0006958 9.81 C3 CD46 MBL2
5 regulation of complement activation GO:0030449 9.78 C3 CD46 CFP
6 inflammatory response GO:0006954 9.77 C3 IL1R1 IL1RN TLR2 TLR4
7 complement activation GO:0006956 9.73 C3 CFP MBL2
8 leukocyte cell-cell adhesion GO:0007159 9.65 EZR MSN
9 positive regulation of interleukin-8 production GO:0032757 9.65 TLR2 TLR4
10 positive regulation of interleukin-6 production GO:0032755 9.65 IL1RN TLR2 TLR4
11 positive regulation of interferon-beta production GO:0032728 9.64 TLR2 TLR4
12 positive regulation of interleukin-12 production GO:0032735 9.63 TLR2 TLR4
13 regulation of cell size GO:0008361 9.63 EZR MSN
14 positive regulation of chemokine production GO:0032722 9.62 TLR2 TLR4
15 establishment of endothelial barrier GO:0061028 9.62 EZR MSN
16 establishment of epithelial cell apical/basal polarity GO:0045198 9.61 EZR MSN
17 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.6 TLR2 TLR4
18 complement activation, alternative pathway GO:0006957 9.59 C3 CFP
19 positive regulation of cellular protein catabolic process GO:1903364 9.58 EZR MSN
20 regulation of cytokine secretion GO:0050707 9.58 TLR2 TLR4
21 I-kappaB phosphorylation GO:0007252 9.57 TLR2 TLR4
22 cellular response to lipoteichoic acid GO:0071223 9.54 TLR2 TLR4
23 gland morphogenesis GO:0022612 9.52 EZR MSN
24 positive regulation of early endosome to late endosome transport GO:2000643 9.51 EZR MSN
25 positive regulation of protein localization to early endosome GO:1902966 9.49 EZR MSN
26 membrane to membrane docking GO:0022614 9.46 EZR MSN
27 innate immune response GO:0045087 9.43 C3 CD46 CFP MBL2 TLR2 TLR4
28 regulation of organelle assembly GO:1902115 9.4 EZR MSN
29 positive regulation of interleukin-10 production GO:0032733 9.33 CD46 TLR2 TLR4
30 interleukin-10 production GO:0032613 9.32 CD46 TLR2
31 positive regulation of cellular response to macrophage colony-stimulating factor stimulus GO:1903974 9.26 TLR2 TLR4
32 immune response GO:0006955 9.1 C3 CFP IL1R1 IL1RN TLR2 TLR4

Molecular functions related to Neisseria Meningitidis Infection according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.26 C3 MBL2 MSN TLR4
2 lipopolysaccharide receptor activity GO:0001875 8.62 TLR2 TLR4

Sources for Neisseria Meningitidis Infection

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....